Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Good morning and welcome to the Amneal Pharmaceuticals First Quarter 2025 Earnings Call. I’d now like to turn the call over to Amneal’s Head of ...

Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio.

Amneal Pharmaceuticals, Inc. ( NASDAQ: AMRX) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

A1c and weight loss were at least as good as semaglutide ... Merck Sharp & Dohme, Metsera, Novartis, Novo Nordisk, Pfizer, Sanofi, and Roche and received grant support paid to his university ...

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

Among the best pharmaceutical stocks, the business’s entry into the fast-growing weight loss and obesity market—through a collaboration with Metsera—positions the company for long-term growth.